Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propan-1,1,2,3,3-d5-ol
- Correlated keywords
- GCMS LCMS nonselective ?adrenergic ?AR ERK-1/2 ?1AR ?2AR ?3AR ?1AR ERK2 cardio-protective BM 14190 BM14190
- Product Overview:
Carvedilol-d5 is intended for use as an internal standard for the quantification of carvedilol (Item No. 15418) by GC- or LC-MS. Carvedilol is a non-selective antagonist of the ?-adrenergic receptor (?-AR; Kds = 1.78, 0.4, and 5.01 nM for ?1-, ?2-, and ?3-ARs, respectively).{25151} It also binds to ?1-, but not ?2-, adrenergic receptors (Kis = 0.81 and 3,400 nM, respectively).{25150} Carvedilol reverses increases in heart rate induced by the ?1-AR agonist isoproterenol (Item No. 15592) in isolated guinea pig atria (Kb = 0.8 nM) and induces relaxation of isolated precontracted guinea pig trachea (Kb = 1.3 nM).{43226} It prevents epinephrine-induced premature ventricular beats in a rat model of arrhythmia with an ED50 value of 0.25 mg/kg.{25150} Carvedilol also inhibits the contractile response to the ?1-AR agonist norepinephrine in isolated rabbit aorta (Kb = 11 nM).{43226} It decreases systolic blood pressure and heart rate in rat models of hypertension, including spontaneously hypertensive, renal hypertensive, and deoxycorticosterone acetate-treated rats when administered at doses ranging from 3 to 30 mg/kg.{43227} Carvedilol also activates cardioprotective signaling through ?-arrestin and ERK1/2 activation.{25152,25153,23372} Formulations containing carvedilol have been used in the treatment of congestive heart failure and hypertension.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.